immunotherapy

Displaying 1 - 10 of 10


Study identifies biomarker for breast cancer response to immunotherapy

A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.


Project seeks new way to assess immunotherapy effectiveness

GE Healthcare has awarded researchers in the Vanderbilt University Institute of Imaging Science (VUIIS) $2.5 million in funding to develop a positron emission tomography (PET) tracer that will determine the effectiveness of immunotherapy in patients early in their treatment course.


Discovery points to new cancer immunotherapy option

An international team involving Vanderbilt researchers has discovered that a new “checkpoint” protein on immune system cells is active in tumors, and that blocking it — in combination with other treatments — is a successful therapeutic approach in mouse models of cancer.


Breast cancer-killing RIG

Immune checkpoint inhibitors — cancer therapies that remove the “brakes” on the adaptive anti-tumor immune response — have had remarkable success in melanoma and lung cancer.


Mary Kay Foundation grant to bolster immunotherapy research

An immunotherapy research initiative at Vanderbilt University Medical Center is among those being supported by the Mary Kay Foundation, which has announced $1.2 million in funding that will be equally shared among 12 cancer research institutions.


Study seeks to boost breast tumor immune response

Immunotherapy, which harnesses the power of the immune system, is one of the most promising forms of cancer therapy and has been shown to work well against some types of cancer. But in early studies, breast cancer has proven to be largely resistant to immunotherapies, which are effective in only about 5 to 10 percent of patients whose tumors have spread or metastasized.